IsoPlexis Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean Mackay
- Full Time Employees
- 290
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 35 NE Industrial Road Branford CT United States of America 06405
- IPO Date
- Oct 8, 2021
- CIK
- 0001615055
- Website
- isoplexis.com
- Similar Companies
- Business
- IsoPlexis Corporation, a biotechnology company, develops and commercializes a single-cell proteomics platform that reveals functional protein biology and cellular signaling networks at single-cell resolution to accelerate therapeutic development for immunotherapies, cell therapies, gene therapies, vaccines, and regenerative medicines; the platform includes the IsoLight and IsoSpark automated benchtop instruments, IsoCode and CodePlex chip consumables for proteomic barcoding, and IsoSpeak software for data analysis and visualization. Founded in 2012 and formerly headquartered in Branford, Connecticut, IsoPlexis targets biopharmaceutical companies, academic institutions, and cancer centers worldwide, with operations spanning the U.S., Europe, and Asia. In March 2023, IsoPlexis merged with Berkeley Lights in an all-stock transaction valued at $57.8 million to form PhenomeX Inc., combining cell biology technologies and customer bases; PhenomeX was subsequently acquired by Bruker Corporation in November 2023 for $108 million in cash, integrating IsoPlexis's products into Bruker Cellular Analysis for expanded functional proteomics applications including T-cell profiling, antibody discovery, and bioprocessing.
Silicon Motion Achieves ISO 26262 Certification for Automotive Applications
Eastman Achieves ISO 59014 Certification, Advancing Leadership in Sustainable Circular Material Recovery
Is Verisk Analytics (VRSK) 42.8% Undervalued After Q1 2026 Earnings? EPS $1.73 vs $1.66 est (beat), Revenue $783M vs $771.42M est (beat) -- GF Score: 82/100
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
OneMeta Achieves ISO/IEC 27001:2022 Certification, Strengthening Secure AI-Driven Multilingual Infrastructure for Business Enterprise and Government Entities
Brenmiller Adds ISO/IEC 42001 Certification to Support AI-Enabled Optimization as Commercial TES Deployments and BNRG360 Strategy Scale
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
Old National Bank, Axletree Solutions Partnership Finalizes Critical Swift Architecture, Achieves ISO 20022 Compliance for 2026
Co-Diagnostics JV, CoSara, Receives ISO 13485 Certification in Preparation for Manufacturing Upcoming PCR Platform
Pega Achieves ISO/IEC 42001:2023 Certification to Provide Clients Comprehensive AI Governance and Trust Standards
Pega Achieves ISO 9001 Certification Underscoring Its Commitment to Quality
WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Earnix Integrates Verisk's ISO ERC™ to Accelerate Adoption for Commercial Market Lines
Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards
Coveo Raises the Bar on Trust: Earns ISO/IEC 27701 Privacy Certification
IFF secures ISO/IEC 27001 certification, elevating global trust in data security and operational excellence